Elasmogen

Executive Summary

Elasmogen is a private UK biopharmaceutical company focused on developing next-generation soloMER™ biologics for solid tumors and inflammatory diseases. Its platform combines high-affinity, site-specific binding with localized small molecule-like activity, aiming to enhance efficacy and safety. Founded in 2005 and based in Aberdeen, Scotland, Elasmogen is currently in the pre-clinical stage with a lead program targeting Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition. The soloMER technology leverages variable domains from immunoglobulin new antigen receptors (VNARs) derived from sharks, offering potential advantages in tissue penetration, stability, and manufacturability. While the company has not disclosed specific funding rounds or valuation, its focus on differentiated biologic modalities positions it in a competitive landscape of novel protein therapeutics. Elasmogen's immediate priority is advancing the HS program toward clinical development. The company is expected to release additional preclinical data and potentially file an investigational new drug (IND) application within the next 12-18 months. Given the high unmet need in HS, which currently lacks effective targeted therapies, successful progression could attract partnership interest from larger pharma. However, as a pre-clinical private company, Elasmogen faces significant development and regulatory risks. Key catalysts include the disclosure of preclinical efficacy and safety data, IND clearance, and potential strategic collaborations. The company's long-term success will depend on translating its platform into clinical proof-of-concept across multiple indications.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data release for HS program60% success
• H1 2027IND filing for lead candidate50% success
• 2026Partnership or licensing deal for soloMER platform40% success